Memory b-cell pools predict the immune response to pneumococcal conjugate vaccine in immunocompromised children

Journal of Infectious Diseases

Volumn 212, Issue 11, 2015, Pages 848-855

  Hoshina, Takayuki ^a   Ohga, Shouichi ^a,d   Fujiyoshi, Junko ^a   Nanishi, Etsuro ^a   Takimoto, Tomoko ^a   Kanno, Shunsuke ^a   Nishio, Hisanori ^a   Saito, Mitsumasa ^b   Akeda, Yukihiro ^e   Oishi, Kazunori ^e,f   Hara, Toshiro ^a,c  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c FUKUOKA CHILDREN S HOSPITAL   (Japan)

^d YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

7 valent pneumococcal conjugate vaccine; After hematopoietic stem cell transplantation; Antipneumococcal immunoglobulin G antibody; Memory B cell; Opsonophagocytic activity

Indexed keywords

CD27 ANTIGEN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE; BACTERIUM ANTIBODY;

ADOLESCENT; ANTIBODY TITER; B LYMPHOCYTE; CD27+ B LYMPHOCYTE; CD27- B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENCE; IMMUNOCOMPROMIZED PATIENT; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LYMPHOCYTE COUNT; MALE; MEMORY CELL; NOTE; OPSONIZATION; PNEUMOCOCCAL INFECTION; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; BLOOD; CD4+ T LYMPHOCYTE; CONTROLLED CLINICAL TRIAL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PNEUMOCOCCAL INFECTIONS;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIGENS, CD27; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; INFANT; PNEUMOCOCCAL INFECTIONS;

EID: 84958650257     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv469     Document Type: Article

References (31)

1. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41
2. CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893-7
3. Chiba N, Morozumi M, Shouji M, et al. Rapid decrease of 7-valent conjugate vaccine coverage for invasive pneumococcal diseases in pediatric patients in Japan. Microb Drug Resist 2013; 19:308-15
4. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1-35
5. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013; 62:521-4
6. Moss SJ, Fenton AC, Toomey JA, Grainger AJ, Smith J, Gennery AR. Responses to a conjugate pneumococcal vaccine in preterm infants immunized at 2, 3, and 4 months of age. Clin Vaccine Immunol 2010; 17:1810-6
7. Sanal O, Ersoy F, Tezcan I, et al. Antibody response to a seven-valent pneumococcal conjugated vaccine in patients with ataxia-telangiectasia. J Clin Immunol 2004; 24:411-7
8. Ladhani SN, Slack MP, Andrews NJ, Waight PA, Borrow R, Miller E. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis 2013; 19:61-8
9. Pao M, Papadopoulos EB, Chou J, et al. Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 2008; 14:1022-30
10. Johannesson TG, Sgaard OS, Tolstrup M, et al. The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults. PLoS One 2012; 7:e42307
11. Leiva LE, Monjure H, Sorensen RU. Recurrent respiratory infections, specific antibody deficiencies, and memory B cells. J Clin Immunol 2013; 33:S57-61
12. Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205:1408-16
13. Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010; 201:1570-9
14. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266-72
15. Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003; 10:514-9
16. Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006; 13:1004-9
17. Honda K, Takada H, Nagatoshi Y, et al. Thymus-independent expansion of T lymphocytes in children after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25:647-52
18. Schuerman L, Wysocki J, Tejedor JC, Knuf M, Kim KH, Poolman J. Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption. Clin Vaccine Immunol 2011; 18:2161-7
19. World Health Organization. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines. World Health Organ Tech Rep Ser 2005; 927:64-98
20. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46
21. Kruetzmann S, Rosado MM,Weber H, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003; 197:939-45
22. Steiniger B, Timphus EM, Jacob R, Barth PJ. CD27+ B cells in human lymphatic organs: re-evaluating the splenic marginal zone. Immunology 2005; 116:429-42
23. Simell B, Nurkka A, Ekstrm N, Givon-Lavi N, Kyhty H, Dagan R. Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine. Clin Vaccine Immunol 2012; 19:1618-23
24. D'Orsogna LJ, Wright MP, Krueger RG, et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells. Biol Blood Marrow Transplant 2009; 15:795-803
25. Avanzini MA, Locatelli F, Dos Santos C, et al. B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells. Exp Hematol 2005; 33:480-6
26. Cuthbert RJ, Iqbal A, Gates A, Toghill PJ, Russell NH. Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol 1995; 48:257-9
27. Lin PL, Michaels MG, Green M, et al. Safety and immunogenicity of the American Academy of Pediatrics-recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 2005; 116:160-7
28. Kapetanovic MC, Roseman C, Jnsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011; 63:3723-32
29. Crnkic Kapetanovic M, Saxne T, Jnsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther 2013; 15:R171
30. Liakou CD, Askiti V, Mitsioni A, Stefanidis CJ, Theodoridou MC, Spoulou VI. Safety and immunogenicity of booster immunization with 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome. Vaccine 2014; 32:1394-7
31. Quinello C, Silveira-Lessa AL, Ceccon ME, Cianciarullo MA, Carneiro-Sampaio MPalmeira P. Phenotypic differences in leucocyte populations among healthy preterm and full-term newborns. Scand J Immunol 2014; 80:57-70